No Data
No Data
Express News | Since April, nearly 10 listed companies have announced illegal short-term transactions involving senior directors and supervisors
Hongyuan Pharmaceutical (301246.SZ): Initial repurchase of 110,000 shares involving 1.960.99 million yuan
Gelonghui, April 8, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that on April 3, 2024, the company repurchased shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 110,000 shares, accounting for 0.0275% of the company's current total share capital. The highest transaction price for the repurchase was 17.92 yuan/share, the minimum transaction price was 17.79 yuan/share, and the total transaction amount was 19.09.85 million yuan (excluding transaction fees).
Hongyuan Pharmaceutical (301246.SZ): Currently, the lithium battery materials industry is experiencing phased overcapacity
Gelonghui, April 8 | Hongyuan Pharmaceutical (301246.SZ) said on the investor interactive platform that the lithium battery materials industry is currently experiencing phased overcapacity, but the lithium battery industry will maintain a relatively rapid growth rate in the long run. In the future, the company will continue to enhance the competitiveness of the company's lithium hexafluorophosphate business through technological iterative upgrading and expansion upstream of the industrial chain. At the same time, it will lay out products such as additives and functional lithium salts, form industrial collaboration with the lithium hexafluorophosphate business, and continue to enhance the business scale and market competitiveness of the company's lithium battery sector. The company strictly complies with regulatory requirements and laws and regulations to fulfill its information disclosure obligations, and the company will pass
Hongyuan Pharmaceutical (301246.SZ): Repurchase has not been implemented
Gelonghui, April 2, 丨 Hongyuan Pharmaceutical (301246.SZ) announced that as of March 31, 2024, the company's special securities account had not implemented operations related to this share repurchase.
Hongyuan Pharmaceutical (301246.SZ): Lithium hexafluorophosphate, one of the main materials for the production of lithium battery electrolytes, has a business cooperation with BYD
Gelonghui March 26 丨 Some investors asked Hongyuan Pharmaceutical (301246.SZ) on the investor interactive platform, “Does the company cooperate with BYD, Xiaomi, Tesla, etc. regarding batteries? Is the company considering entering the robot battery industry?” The company replied that lithium hexafluorophosphate, one of the main materials for lithium battery electrolytes, has business cooperation with BYD. Please pay attention to the company's subsequent announcements for future investments in the field of new energy batteries.
A-share changes丨Hongyuan Pharmaceutical plummeted by more than 13% and 112 million restricted shares were lifted today
Gelonghui, March 20 | Affected by the lifting of the share ban, Hongyuan Pharmaceutical (301246.SZ) plummeted by more than 13% at the beginning of the session. The decline temporarily ranked first in the market. The stock price fell below the 20 yuan mark, with a total market value of 7.8 billion yuan. According to news, the company lifted the listing ban on 112 million restricted shares today, making it the company's initial shareholder's restricted shares, accounting for 27.94% of the company's total share capital. After the ban was lifted, the company still has 252 million restricted shares, accounting for 62.88% of the total share capital.
No Data